BridgeBio Oncology will present BBO-10203 data at SABCS, targeting RAS-related cancer treatment efficacy and safety.
Quiver AI Summary
BridgeBio Oncology Therapeutics, Inc. (BBOT) has announced two upcoming poster presentations featuring their novel therapeutic candidate, BBO-10203, at the San Antonio Breast Cancer Symposium (SABCS) from December 9-12, 2025. BBO-10203 is a first-in-class, orally bioavailable agent that selectively disrupts the interaction between RAS and PI3Kα, demonstrating potential to inhibit tumor growth in breast cancer models without causing hyperglycemia. The presentations include findings from a pre-clinical study and details of a Phase 1a/1b clinical trial evaluating the safety and effectiveness of BBO-10203 in patients with advanced solid tumors, including specific breast and lung cancers. BBOT aims to develop innovative treatments targeting prevalent oncogenes to enhance cancer patient outcomes.
Potential Positives
- Announcement of two poster presentations at the San Antonio Breast Cancer Symposium highlights the company’s commitment to innovation in oncology, specifically targeting RAS-pathway malignancies.
- Introduction of BBO-10203, a first-in-class treatment, indicates a novel approach to cancer therapy that may offer advantages over existing treatments, particularly in avoiding hyperglycemia.
- The potential applicability of BBO-10203 to various tumor types expands the company's therapeutic reach and could attract significant interest from investors and healthcare professionals.
Potential Negatives
- The press release highlights that BBO-10203 is still in the Phase 1 clinical trial stage, indicating the product is not yet approved for market and poses uncertainty regarding its future commercial viability.
- The poster presentations are focused on pre-clinical and early-stage trial information, which may not be as newsworthy or impactful compared to late-stage trial results or FDA approvals, potentially reflecting a lack of significant progress in their drug development pipeline.
- The mention of past negative impacts from similar compounds related to hyperglycemia could raise concerns regarding the long-term safety profile of BBO-10203, despite its claim of not inducing hyperglycemia.
FAQ
What is BBO-10203?
BBO-10203 is a first-in-class, orally bioavailable small molecule that inhibits the RAS:PI3Kα interaction in tumors.
When will the SABCS presentations take place?
The presentations will occur from December 9-12, 2025, at the San Antonio Breast Cancer Symposium.
What does the BREAKER-101 trial evaluate?
The BREAKER-101 trial assesses the safety, tolerability, pharmacokinetics, and efficacy of BBO-10203 in patients with advanced solid tumors.
Who is presenting the BBO-10203 research?
Kerstin Sinkevicius, PhD, will present pre-clinical data, while Andreas Varkaris, MD, PhD, will present trial details at SABCS.
What cancers is BBO-10203 targeting?
BBO-10203 targets HER2+ amplified or HR+/HER2- breast cancer, and KRAS mutant colorectal or non-small cell lung cancer.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$BBOT Analyst Ratings
Wall Street analysts have issued reports on $BBOT in the last several months. We have seen 2 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- HC Wainwright & Co. issued a "Buy" rating on 09/15/2025
- Wedbush issued a "Outperform" rating on 08/18/2025
To track analyst ratings and price targets for $BBOT, check out Quiver Quantitative's $BBOT forecast page.
$BBOT Price Targets
Multiple analysts have issued price targets for $BBOT recently. We have seen 4 analysts offer price targets for $BBOT in the last 6 months, with a median target of $25.0.
Here are some recent targets:
- Andrew Berens from Leerink Partners set a target price of $25.0 on 09/17/2025
- Robert Burns from HC Wainwright & Co. set a target price of $27.0 on 09/15/2025
- Matthew Biegler from Oppenheimer set a target price of $23.0 on 09/04/2025
- David Nierengarten from Wedbush set a target price of $25.0 on 08/18/2025
Full Release
SOUTH SAN FRANCISCO, Calif., Oct. 30, 2025 (GLOBE NEWSWIRE) -- BridgeBio Oncology Therapeutics, Inc. (“BBOT”) (Nasdaq: BBOT), a clinical-stage biopharmaceutical company focused on RAS-pathway malignancies, today announced two poster presentations featuring BBO-10203, a first-in-class, orally bioavailable, selective breaker of the RAS:PI3Kα interaction, at the San Antonio Breast Cancer Symposium (SABCS) being held December 9-12, 2025, in San Antonio, Texas. The abstracts released today can be found on the SABCS website here .
Late Breaking Pre-clinical Poster Details:
- Title: BBO-10203, a first-in-class breaker of the RAS:PI3Kα interaction, inhibits tumor growth alone and in combination with fulvestrant or ribociclib in breast cancer models without inducing hyperglycemia
- Presentation Number: PS2-12-06
- Abstract Number: 3568
- Session Date/Time : Wednesday, December 10, from 5:00 p.m. - 6:30 p.m. CT
-
Presenter
: Kerstin Sinkevicius, PhD, Vice President, Pharmacology, BBOT
Trials in Progress Poster Details:
- Title: BREAKER-101: a phase 1a/1b open-label study evaluating the safety, tolerability, pharmacokinetics, and efficacy of BBO-10203 in patients with advanced solid tumors
- Presentation Number: PS5-07-06
- Abstract Number: 203
- Session Date/Time : Friday, December 12, from 12:30 p.m. – 2:00 p.m. CT
-
Presenter
: Andreas Varkaris, MD, PhD, Attending Physician and Investigator, Massachusetts General Hospital
About BBO-10203
BBO-10203 (NCT06625775) is an orally bioavailable small molecule that selectively and specifically blocks the physical interaction between RAS and PI3Kα, resulting in the inhibition of RAS-driven PI3Kα-AKT signaling in tumors without the risk of hyperglycemia. This novel mechanism of action makes BBO-10203 agnostic to the mutational status of either
RAS
or
PI3Kα
providing the potential to treat tumors driven by
KRAS
or
PI3Kα
mutations, the two most mutated oncogenes in human cancer. BBO-10203 is being evaluated in the Phase 1 BREAKER-101 trial for patients with HER2+ amplified or HR+/HER2- breast cancer, and
KRAS
mutant colorectal or non-small cell lung cancer.
About BBOT
BBOT is a clinical-stage biopharmaceutical company advancing a next-generation pipeline of novel small molecule therapeutics targeting RAS and PI3Kα malignancies. BBOT has the goal of improving outcomes for patients with cancers driven by the two most prevalent oncogenes in human tumors. For more information, please visit
www.bbotx.com
and follow us on
LinkedIn
.
BBOT Contacts:
Investor Contact:
Heather Armstrong, Head of Investor Relations
BBOT
[email protected]
Media Contact:
Jake Robison
Inizio Evoke Comms
[email protected]
